| __timestamp | Dynavax Technologies Corporation | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 79529000 |
| Thursday, January 1, 2015 | 22180000 | 91224000 |
| Friday, January 1, 2016 | 37257000 | 102413000 |
| Sunday, January 1, 2017 | 27367000 | 146987000 |
| Monday, January 1, 2018 | 64770000 | 213695000 |
| Tuesday, January 1, 2019 | 74986000 | 342000000 |
| Wednesday, January 1, 2020 | 79256000 | 661000000 |
| Friday, January 1, 2021 | 100156000 | 1283000000 |
| Saturday, January 1, 2022 | 131408000 | 2676000000 |
| Sunday, January 1, 2023 | 152946000 | 3297000000 |
| Monday, January 1, 2024 | 3790000000 |
Unveiling the hidden dimensions of data
In the dynamic world of biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Genmab A/S has shown a remarkable increase in SG&A spending, growing by over 4,000%, from approximately $80 million in 2014 to nearly $3.3 billion in 2023. This surge reflects Genmab's aggressive expansion and investment in its operational capabilities. In contrast, Dynavax Technologies Corporation's SG&A expenses have increased by about 760%, from $18 million to $153 million, indicating a more conservative growth strategy. These spending patterns highlight the differing strategic approaches of these two companies in navigating the competitive biotech landscape. As the industry evolves, monitoring such financial metrics will be key to understanding future market dynamics.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Dynavax Technologies Corporation
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Rhythm Pharmaceuticals, Inc. vs Dynavax Technologies Corporation
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.